본문 바로가기
KERD
논문KCI 등재

고혈압 약제의 병용요법

Combination therapy of hypertension

2

조회

0

다운로드

0

인용

0

참고문헌

키워드

주제분류내과학

초록

Hypertension is one of the most common preventable disease for premature death in worldwide. In Korea, the prevalence rate of hypertension is 24.9% in adult. The pathophysiology of the hypertension is complicated including genetics, aging, sympathetic nervous system, renin-angiotensin-aldosterone system, metabolism and nutrition. The combination therapy for blocking these complex systems is effective. Recent clinical studies showed angiotensin converting enzyme inhibitor and calcium channel blocker was more effective than the old drug combination such as beta blocker and diuretics. For improving compliance, fixed-dose drug combination is recommended. For the effect of treatment, simple guideline is essential.

Abstract

Hypertension is one of the most common preventable disease for premature death in worldwide. In Korea, the prevalence rate of hypertension is 24.9% in adult. The pathophysiology of the hypertension is complicated including genetics, aging, sympathetic nervous system, renin-angiotensin-aldosterone system, metabolism and nutrition. The combination therapy for blocking these complex systems is effective. Recent clinical studies showed angiotensin converting enzyme inhibitor and calcium channel blocker was more effective than the old drug combination such as beta blocker and diuretics. For improving compliance, fixed-dose drug combination is recommended. For the effect of treatment, simple guideline is essential.

참고문헌 (32)

  1. Ezzati M, "Selected major risk factors and global and regional burden of disease", Lancet, 360, pp.1347~1360 (2002)
  2. 대한고혈압학회, "고혈압 1st ed", pp.7~ (2009), 대한의학서적
  3. Williams B, "The Year in Hypertension", J Am Coll Card, 48, pp.1698~1711 (2006)
  4. UK Prospective Diabetes Study Group, "Tight blood pressure control and risk of macrovascular and microvascular complications in Type 2 diabetes : UKPDS 38", BMJ, 317, pp.703~713 (1998)
  5. Fauci, "Harrison’s principles of internal medicine, 17th ed", pp.1550~1552 (2008), Mc Graw Hill Medical
  6. Hansson L, "Effect of intensive blood pressure-lowering and low-dose aspirin in patients with hypertension : principal results of the Hypertension Optimal Treatment(HOT) randomized trial", Lancet, 351, pp.1755~1762 (1998)
  7. Winker MA, "Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final result of the systolic hypertension in elderly program(SHEP)", JAMA, 265, pp.3255~3264 (1991)
  8. Dahlöf B, "LIFE Study Group. cardiovascular morbidity and mortality in the losartan intervention for endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol", Lancet, 359, pp.995~1003 (2002)
  9. Julius S, "VALUE trial group. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomized trial", Lancet, 363, pp.2022~2031 (2004)
  10. Chobanian AV, "Seventh report of the Joint National Conmmittee on Prevention, Ditection, and Treatment of High Blood Pressure", Hypertension, 42, pp.1206~1252 (2003)
  11. Mancia G, "2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC)", J Hypertens, 25, pp.1105~1187 (2007)
  12. Dahlöf B, "ASCOT Investigators. ASCOT investigators Prevention of cardiovascular events with a antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendoflumethiazide as required, in the anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm(ASCOT-BPLA): a multicenter randomized controlled trial", Lancet, 366, pp.895~906 (2005)
  13. Jamerson K, "ACCOMPLISH Trial Investigators. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients", N Engl J Med, 359, pp.2417~2428 (2008)
  14. Yusuf S, "Telmisartan, ramipril or both in patients at high risk for vascular events", N Engl J Med, 358, pp.1547~1559 (2008)
  15. Beckett NS, "HYVET Study Group. Treatment of hypertension in patients 80 years old age or older for the HYVET Study", New Engl J Med, 358, pp.1887~1898 (2008)
  16. Yusuf S, "PRoFESS Study Group. for the PRoFESS study group. Telmisartan to prevent recurrent stroke and cardiovascular events", New Engl J Med, 359, pp.1225~1237 (2008)
  17. The Heart Outcomes Prevention Evaluation Study Investigators, "Effect of an angiotensin-converting-enzyme inhibitor, ramipril on cardiovascular events in high risk patients", N Engl J Med, 342, pp.145~153 (2000)
  18. The ALLHAT Officers and Coordinattors for the ALLHAT Collaborative RESEARCH Group, "Major Outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic:The Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial(ALLHT)", JAMA, 288, pp.2981~2997 (2002)
  19. The ALLHAT Officers and Coordinattors for the ALLHAT Collaborative RESEARCH Group, "Major Outcomes in high-risk hypertensive patients randomly assigned to Doxazocin vs chlorothalidone: the antihypertensive and lipid lowering treatment to prevent heart attack trial(ALLHAT)", JAMA, 283, pp.1967~1975 (2002)
  20. Williams B, "Guidelines for management of hypertension: report of the fourth working party of Britisch Hypertension Siciety, 2004-BHS IV", Journal of Human Hypertension, 18, pp.139~185 (2004), British Hypertension Society
  21. Fagard RH, "Regression of left ventricular mass by antihypertensive treatment A meta-analysis of randomized comparative studies", Hypertension, 54, pp.1084~1091 (2009)
  22. Cooper-DeHoff RM, "Impact of abdominal obesity on incidence of adverse metabolic effects associated with antihypertensive medications", Hypertension, 1, pp.5561~5568 (2010)
  23. Manrique C, "Thiazide diuretics alone or with B-blockers impair glucose metabolism in hypertensive patients with abdominal obesity", Hypertension, 55, pp.15~17 (2010)
  24. Messerli FH, "A meta-analysis of 94,492 patients with hypertension treated with beta blockers to determine the risk of new-onset diabetes mellitus", Am J Cardiol, 8, pp.1254~1262 (2007)
  25. Williams B, "Impact of heart rate on central aortic pressures and hemodynamics: analysis from the CAFE (Conduit Artery Function Evaluation) study: CAFE-Heart Rate", J Am Coll Cardiol, 18, pp.705~713 (2009)
  26. Papadopoulos DP, "Aggressive bloodpressure control and stroke prevention : role of calcium channel blockers", J Hypertenision, 26, pp.844~852 (2008)
  27. Fedorowski A, "Orthostatic hypotension predicts all-cause mortality and coronary events in middle-aged individuals (The Malmo¨ Preventive Project)", Eur Heart J, 31, pp.85~91 (2009)
  28. O’Brien E, "Aliskiren reduces blood pressue and suppresses plasma rennin activity in combination with a thiazide diuretic, an angiotensin-converting enzyme inhibitor, or an angiotensin receptor blocker", Hypertension, 49, pp.276~284 (2009)
  29. Menard J, "The difficult conception, birth and delivery of a rennin inhibitor: controversies around aliskiren", J Hypertenision, 25, pp.1775~1782 (2007)
  30. Calhoun DA, "Triple antihypertensive therapy with amlodipine, valsartan, and hydrochlorothiazide a randomized clinical trial", Hypertension, 54, pp.32~39 (2009)
  31. Sharp A, "Ethnicity and left ventricular diastolic function in hypertension An ASCOT Substudy", J Am Coll Cardiolo, 52, pp.1015~1021 (2008)
  32. Feldman RD, "A simplified approach to the treatment of uncomplicated hypertension A cluster randomized, controlled trial", Hypertension, 53, pp.646~653 (2009)

관련 논문AI추천

이 간행물의 다른 논문 (11건)